Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – (Business Wire) -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – December 2, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, said today that Curtis L. Ruegg, Ph.D. will join the company as its...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Selectivity of AMV564 Presents Opportunity in Patients with Solid Tumors South San Francisco, CA – November 7, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, will present at...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Amphivena to advance AMV564 in a Multi-Center Dose Finding Phase 1 Clinical Study in Patients with Solid Tumors South San Francisco, CA -- October 16, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell...

South San Francisco, CA – July 1, 2019 -- Amphivena Therapeutics, Inc., highlighted initial data from the dose escalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML, AMV564-101, NCT03144245) in an oral presentation June...

[fluid][html css="margin-top:23px;"] SOUTH SAN FRANCISCO – March 5, 2019 -- Amphivena Therapeutics, Inc., a privately held clinical stage immuno-oncology (I/O) company that develops T cell engager therapeutics for myeloid malignancies and solid tumors, announced today the appointment of Victoria Smith, Ph.D. to the position of Chief...